Morgan Stanley Initiates Coverage on WuXi PharmaTech (WX)
More News related to WX
- WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services
- WuXi PharmaTech to Present at 20th Annual Piper Jaffray Healthcare Conference
- WuXi PharmaTech (X) Reports Mixed Q3 Earnings; Reaffirms FY08 Outlook
- WuXi PharmaTech Appoints Ying Han to Its Board of Directors
- WuXi PharmaTech Announces Third Quarter 2008 Results
More News related to New Coverage
- Raymond James Starts Millicom (MICC) at Strong Buy
- Stifel Nicolaus Starts City National (CYN) at Hold
- Stifel Nicolaus Starts eHealth (Nasdaq: HLTH) with a Buy
- Wasserman & Associates initiates coverage on American Physicians Service Group (AMPH) with a Buy
- Jesup & Lamont Initiates Coverage on AutoZone (AZO) with a Hold.
Morgan Stanley initiates coverage on WuXi PharmaTech (NYSE: WX) with an Overweight.
WuXi PharmaTech (Cayman) Inc. (WuXi) is a pharmaceutical, biotechnology and medical device research and development (R&D) outsourcing company, with operations in China and the United States.
Related Categories
New CoverageStocks Mentioned
-0.95Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
